Taiko Pharmaceutical Co (TSE:4574) Total Receivables: 円2,449 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4574 Taiko Pharmaceutical Co Ltd TSE:4574
64 GF Score
Price 円276.00
GF Value 円352.09
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Taiko Pharmaceutical Co Total Receivables?

Taiko Pharmaceutical Co TSE:4574 +3.37% 64 Total Receivables is 円2,449 Mil as of Dec. 2025. GuruFocus rates TSE:4574 with a GF Score™ of 64/100 and a GF Value™ of 円352.09 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Taiko Pharmaceutical Co's Total Receivables for the quarter that ended in Dec. 2025 was 円2,449 Mil.

Taiko Pharmaceutical Co Total Receivables Related Terms

Taiko Pharmaceutical Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Taiko Pharmaceutical Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Total Receivables Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,056.00 1,798.00 1,985.00 2,427.00 2,449.00

Taiko Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,716.00 1,719.00 2,020.00 2,449.00 1,533.00
TSE:4574
64GF Score
Taiko Pharmaceutical Co Ltd TSE:4574
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiko Pharmaceutical Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of 円2,449 Mil mean?
Taiko Pharmaceutical Co (TSE:4574) has a Total Receivables of 円2,449 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Taiko Pharmaceutical Co and its competitors.
Is Taiko Pharmaceutical Co's Total Receivables too high?
Taiko Pharmaceutical Co's current Total Receivables is 円2,449 Mil. Overall, Taiko Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Total Receivables compare to ZTS and UTHR?
Taiko Pharmaceutical Co's Total Receivables of 円2,449 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Taiko Pharmaceutical Co and its competitors. Taiko Pharmaceutical Co's current Total Receivables is 円2,449 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Modestly Undervalued. The stock's GF Value™ is 円352.09, compared to a current price of 円276.00 — trading 21.6% below its estimated fair value. The current Total Receivables is 円2,449 Mil. Taiko Pharmaceutical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Total Receivables is 円2,449 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?

Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued. The current stock price of 円276.00 is trading 21.6% below its estimated GF Value™ of 円352.09. GuruFocus considers Taiko Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4574:

  • Total Receivables: 円2,449 Mil
  • GF Value™: 円352.09 vs. price of 円276.00 (21.6% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiko Pharmaceutical Co Business Description

Address 1-4-1 Nishihonmachi, 16th Floor, ORIX Honmachi Building, Nishi-ku, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
64GF Score

Get the complete analysis for TSE:4574

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円276.00
Price
円352.09
GF Value